{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T22:17:15Z","timestamp":1784067435253,"version":"3.55.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejpn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Paediatric Neurology"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.ejpn.2023.07.008","type":"journal-article","created":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T12:02:09Z","timestamp":1690891329000},"page":"6-12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Gaboxadol in angelman syndrome: A double-blind, parallel-group, randomized placebo-controlled phase 3 study"],"prefix":"10.1016","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8046-3376","authenticated-orcid":false,"given":"Christopher","family":"Keary","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4833-3747","authenticated-orcid":false,"given":"Lynne M.","family":"Bird","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Claire","family":"de Wit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivkumar","family":"Hatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gali","family":"Heimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Heussler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Kolevzon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adera","family":"Mathews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesar","family":"Ochoa-Lubinoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Hann","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3168-8706","authenticated-orcid":false,"given":"Ying","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5021-0135","authenticated-orcid":false,"given":"Maxwell","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ejpn.2023.07.008_bib1","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1002\/ajmg.1320280407","article-title":"Is Angelman syndrome an alternate result of del(15)(q11q13)?","volume":"28","author":"Magenis","year":"1987","journal-title":"Am. J. Med. Genet."},{"issue":"30","key":"10.1016\/j.ejpn.2023.07.008_bib2","doi-asserted-by":"crossref","first-page":"9958","DOI":"10.1523\/JNEUROSCI.1728-10.2010","article-title":"Angelman syndrome, a genomic imprinting disorder of the brain","volume":"30","author":"Chamberlain","year":"2010","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.ejpn.2023.07.008_bib3","unstructured":"Dagli AI, Mueller J, Williams CA: Angelman Syndrome. GeneReviews\u00ae. Posted September 15, 1998. Revised December 21, 2017. Available at: ncbi.nlm.nih.gov\/books\/NBK1144\/[Accessed March 28, 2022]."},{"issue":"6","key":"10.1016\/j.ejpn.2023.07.008_bib4","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1093\/hmg\/ddab050","article-title":"Loss of nuclear UBE3A activity is the predominant cause of Angelman syndrome in individuals carrying UBE3A missense mutations","volume":"30","author":"Bossuyt","year":"2021","journal-title":"Hum. Mol. Genet."},{"issue":"9\u201310","key":"10.1016\/j.ejpn.2023.07.008_bib5","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s10354-015-0408-z","article-title":"Pharmacological therapies for Angelman syndrome","volume":"167","author":"Tan","year":"2017","journal-title":"Wien Med. Wochenschr."},{"issue":"10","key":"10.1016\/j.ejpn.2023.07.008_bib7","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nrneurol.2016.133","article-title":"Angelman syndrome - insights into a rare neurogenetic disorder","volume":"12","author":"Buiting","year":"2016","journal-title":"Nat. Rev. Neurol."},{"issue":"5","key":"10.1016\/j.ejpn.2023.07.008_bib8","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/ajmg.a.31074","article-title":"Angelman syndrome 2005: updated consensus for diagnostic criteria","volume":"140","author":"Williams","year":"2006","journal-title":"Am. J. Med. Genet."},{"issue":"1","key":"10.1016\/j.ejpn.2023.07.008_bib9","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/ajmg.a.61382","article-title":"An overview of health issues and development in a large clinical cohort of children with Angelman syndrome","volume":"182","author":"Bindels-de Heus","year":"2020","journal-title":"Am. J. Med. Genet."},{"issue":"1","key":"10.1016\/j.ejpn.2023.07.008_bib10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.neuron.2011.12.012","article-title":"Extrasynaptic GABA(A) receptors: their function in the CNS and implications for disease","volume":"73","author":"Brickley","year":"2012","journal-title":"Neuron"},{"key":"10.1016\/j.ejpn.2023.07.008_bib11","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3389\/fncel.2014.00119","article-title":"Modulation of GABAergic transmission in development and neurodevelopmental disorders: investigating physiology and pathology to gain therapeutic perspectives","volume":"8","author":"Deidda","year":"2014","journal-title":"Front. Cell. Neurosci."},{"issue":"163","key":"10.1016\/j.ejpn.2023.07.008_bib12","doi-asserted-by":"crossref","first-page":"163ra157","DOI":"10.1126\/scitranslmed.3004655","article-title":"Decreased tonic inhibition in cerebellar granule cells causes motor dysfunction in a mouse model of Angelman syndrome","volume":"4","author":"Egawa","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejpn.2023.07.008_bib13","first-page":"170","article-title":"Pathophysiological power of improper tonic GABA(A) conductances in mature and immature models","volume":"7","author":"Egawa","year":"2013","journal-title":"Front. Neural Circ."},{"issue":"4","key":"10.1016\/j.ejpn.2023.07.008_bib14","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S0896-6273(00)80596-6","article-title":"Mutation of the Angelman ubiquitin ligase in mice causes increased cytoplasmic p53 and deficits of contextual learning and long-term potentiation","volume":"21","author":"Jiang","year":"1998","journal-title":"Neuron"},{"issue":"4","key":"10.1016\/j.ejpn.2023.07.008_bib15","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1002\/ajmg.c.31536","article-title":"Angelman syndrome: current and emerging therapies in 2016","volume":"172","author":"Tan","year":"2016","journal-title":"Am J Med Genet C Semin Med Genet"},{"issue":"1","key":"10.1016\/j.ejpn.2023.07.008_bib16","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s13023-017-0716-z","article-title":"Unmet clinical needs and burden in Angelman syndrome: a review of the literature","volume":"12","author":"Wheeler","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"issue":"2","key":"10.1016\/j.ejpn.2023.07.008_bib17","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1365-2125.2008.03331.x","article-title":"Tolerability, pharmacokinetics and night-time effects on postural sway and critical flicker fusion of gaboxadol and zolpidem in elderly subjects","volume":"67","author":"Boyle","year":"2009","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.ejpn.2023.07.008_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.bjp.0704846","article-title":"Characterization of GABA(A) receptor ligands in the rat cortical wedge preparation: evidence for action at extrasynaptic receptors?","volume":"137","author":"Ebert","year":"2002","journal-title":"Br. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.ejpn.2023.07.008_bib19","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1152\/jn.00450.2011","article-title":"Molecular basis for the high THIP\/gaboxadol sensitivity of extrasynaptic GABA(A) receptors","volume":"106","author":"Meera","year":"2011","journal-title":"J.\u00a0Neurophysiol."},{"issue":"7","key":"10.1016\/j.ejpn.2023.07.008_bib20","doi-asserted-by":"crossref","first-page":"e1024","DOI":"10.1212\/WNL.0000000000011409","article-title":"The STARS phase 2 study: a randomized controlled trial of gboxadol in Angelman syndrome","volume":"96","author":"Bird","year":"2021","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.ejpn.2023.07.008_bib21","first-page":"28","article-title":"The clinical global impressions scale: applying a research tool in clinical practice","volume":"4","author":"Busner","year":"2007","journal-title":"Psychiatry"},{"issue":"1","key":"10.1016\/j.ejpn.2023.07.008_bib22","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s11689-020-09349-8","article-title":"Development of an adapted clinical global impression scale for use in angelman syndrome","volume":"13","author":"Kolevzon","year":"2021","journal-title":"J.\u00a0Neurodev. Disord."},{"key":"10.1016\/j.ejpn.2023.07.008_bib23","article-title":"An adapted Clinical Global Impression of Improvement for use in Angelman Syndrome: validation analyses utilizing data from the NEPTUNE study","author":"Ventola","year":"2022","journal-title":"Eur. J. Paediatr. Neurol."},{"issue":"9","key":"10.1016\/j.ejpn.2023.07.008_bib24","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.4088\/JCP.v67n0914","article-title":"What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder?","volume":"67","author":"Bandelow","year":"2006","journal-title":"J.\u00a0Clin. Psychiatry"},{"issue":"5","key":"10.1016\/j.ejpn.2023.07.008_bib25","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1002\/ajmg.a.38457","article-title":"A\u00a0randomized controlled trial of levodopa in patients with Angelman syndrome","volume":"176","author":"Tan","year":"2018","journal-title":"Am. J. Med. Genet."},{"issue":"1","key":"10.1016\/j.ejpn.2023.07.008_bib26","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13229-020-00372-z","article-title":"Placebo response in pharmacological and dietary supplement trials of autism spectrum disorder (ASD): systematic review and meta-regression analysis","volume":"11","author":"Siafis","year":"2020","journal-title":"Mol. Autism."},{"issue":"3","key":"10.1016\/j.ejpn.2023.07.008_bib27","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S2215-0366(21)00429-6","article-title":"Efficacy and safety of balovaptan for socialisation and communication difficulties in autistic adults in North America and Europe: a phase 3, randomised, placebo-controlled trial","volume":"9","author":"Jacob","year":"2022","journal-title":"Lancet Psychiatr."},{"issue":"3","key":"10.1016\/j.ejpn.2023.07.008_bib28","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S2215-0366(21)00504-6","article-title":"Placebo effects and participant heterogeneity in clinical trials of autism spectrum disorder","volume":"9","author":"Loth","year":"2022","journal-title":"Lancet Psychiatr."},{"issue":"9","key":"10.1016\/j.ejpn.2023.07.008_bib29","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci10090629","article-title":"Response to placebo in fragile X syndrome clinical trials: an initial analysis","volume":"10","author":"Luu","year":"2020","journal-title":"Brain Sci."}],"container-title":["European Journal of Paediatric Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090379823001289?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090379823001289?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T18:40:50Z","timestamp":1761072050000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1090379823001289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":28,"alternative-id":["S1090379823001289"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpn.2023.07.008","relation":{},"ISSN":["1090-3798"],"issn-type":[{"value":"1090-3798","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gaboxadol in angelman syndrome: A double-blind, parallel-group, randomized placebo-controlled phase 3 study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Paediatric Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpn.2023.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Ltd on behalf of European Paediatric Neurology Society.","name":"copyright","label":"Copyright"}]}}